Surgical Oncology-Oxford最新文献

{"title":"Effect of antiviral treatment for hepatitis C virus on long-term outcomes in patients undergoing resection for hepatocellular carcinoma","authors":"Hiroyuki Hakoda,&nbsp;Yoshikuni Kawaguchi,&nbsp;Yujiro Nishioka,&nbsp;Yuichiro Mihara,&nbsp;Akihiko Ichida,&nbsp;Takeshi Takamoto,&nbsp;Nobuhisa Akamatsu,&nbsp;Kiyoshi Hasegawa","doi":"10.1016/j.suronc.2025.102255","DOIUrl":"10.1016/j.suronc.2025.102255","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis C virus infection is a risk factor for hepatocellular carcinoma (HCC). The effect of direct-acting antivirals on prognoses remains unclear. We assessed the prognosis of patients receiving direct-acting antiviral and interferon treatment after the initial resection of hepatitis C virus-related HCC.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed patients who underwent initial hepatitis C virus-related HCC resection at The University of Tokyo Hospital between June 2009 and December 2022. Recurrence-free survival (RFS) and overall survival (OS) were assessed using the log-rank test. Cox proportional hazards model analysis was performed to identify the risk factors for RFS and OS.</div></div><div><h3>Results</h3><div>Of 756 patients who underwent HCC resection, 142 had hepatitis C virus-related HCC. Among them, the 5-year OS was significantly better in those receiving antiviral treatment than in those without antiviral treatment (72.2 % vs. 48.9 %, P &lt; 0.001); however, RFS did not differ between the groups (P = 0.35). RFS and OS did not differ significantly between patients who received direct-acting antivirals and those who received interferon (P = 0.09 and P = 0.47, respectively). RFS and OS did not differ significantly between patients receiving antiviral treatment before surgery and those after surgery (P = 0.11 and P = 0.23, respectively).</div></div><div><h3>Conclusions</h3><div>Antiviral treatment improved postoperative prognosis; however, the prognosis did not differ between the types of antiviral treatment in patients with hepatitis C virus-related hepatocellular carcinoma.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"62 ","pages":"Article 102255"},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Qaly study: Quality of life and lower extremity lymphedema in 174 patients after inguinal lymphadenectomy","authors":"Brett A. Hahn ,&nbsp;Alieske Kleeven ,&nbsp;Milan C. Richir ,&nbsp;Arjen J. Witkamp ,&nbsp;Anke M.J. Kuijpers ,&nbsp;Kristien B.M.I. Keymeulen ,&nbsp;J. Henk Coert ,&nbsp;Shan Shan Qiu ,&nbsp;David D. Krijgh","doi":"10.1016/j.suronc.2025.102257","DOIUrl":"10.1016/j.suronc.2025.102257","url":null,"abstract":"<div><h3>Background</h3><div>Lower extremity lymphedema (LEL) can develop in patients who undergo inguinal lymph node dissection (ILND) in the treatment of gynecologic, genitourinary, and skin and soft tissue malignancies. While LEL can negatively impact quality of life, the poorly documented prevalence and severity of lymphedema-related symptoms complicates the ability to identify high-risk patients and improve the selection of candidates for emerging microsurgical interventions.</div></div><div><h3>Methods</h3><div>This multicenter, cross-sectional study included patients who underwent ILND between 1990 and 2022 across three medical centers in the Netherlands. Retrospective clinical data, including demographic, surgical, and postoperative variables, were abstracted from medical records. Lymphedema prevalence and severity were assessed using the Lymph-ICF-LL questionnaire, while additional patient-reported outcome measures (PROMs) evaluated quality of life and lower extremity function. Statistical analyses included multivariate logistic and linear regression to identify predictors of lymphedema-related symptoms and their impact on PROMs.</div></div><div><h3>Results</h3><div>Among 174 patients who underwent ILND, 77 % reported lymphedema-related symptoms, which were associated with significantly lower quality of life. Multivariable analysis identified that younger age at time of surgery, medical history of cardiovascular disease, and postoperative complications such as surgical site infections (SSI) and prolonged wound healing were significant predictors of developing lymphedema-related symptoms. Additionally, the presence of lymphedema was strongly linked to poorer physical and mental health PROMs, with malignancy type and surgical factors influencing these outcomes.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the significant burden of lymphedema-related symptoms following ILND, while highlighting the potential role of reconstructive microsurgery in reducing morbidity for high-risk patients.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"62 ","pages":"Article 102257"},"PeriodicalIF":2.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144588534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trend shift from autologous to implant-based breast reconstruction","authors":"Ekaterina Nedeoglo ,&nbsp;Philipp Moog ,&nbsp;Jun Jiang ,&nbsp;Inessa Suhova ,&nbsp;Hans-Günther Machens ,&nbsp;Kai Megerle ,&nbsp;Haydar Kükrek","doi":"10.1016/j.suronc.2025.102256","DOIUrl":"10.1016/j.suronc.2025.102256","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is the most common type of cancer in women and advances in treatment have shifted the focus towards improving quality of life. Breast reconstruction plays a crucial role in preserving body image for patients undergoing mastectomy. However, significant variations exist in breast reconstruction choices across different countries. Understanding national trends can help optimize patient-centered care.</div></div><div><h3>Methods</h3><div>Using data from quality reports, we analyzed breast reconstruction trends in Germany from 2012 to 2021. The study examined overall reconstruction rates, the distribution of reconstruction methods (implant-based vs. autologous), and differences between surgical departments.</div></div><div><h3>Results</h3><div>Breast reconstruction rates in Germany have steadily increased, with up to 38 % of mastectomy patients undergoing reconstruction. The number of implant-based reconstructions rose significantly by nearly 70 % during this period. Most reconstructions were performed in gynecology departments, where the highest increase in implant-based procedures was observed.</div></div><div><h3>Conclusion</h3><div>The reasons for the shift towards implant-based reconstruction are speculative. The increase in contralateral prophylactic mastectomies, the lack of collaboration with plastic surgery departments and the complexity of autologous breast reconstruction could all be plausible explanations for this observation. Further analysis and critical evaluation of current trends are essential to ensure an individualized, patient-centered approach to breast reconstruction surgery.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"62 ","pages":"Article 102256"},"PeriodicalIF":2.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Tilmanocept based lymphoscintigraphy measure up against colloid-based lymphoscintigraphy for sentinel node biopsy in melanoma and early oral squamous cell cancer?","authors":"Giuleta Jamsari ,&nbsp;Eva Wong ,&nbsp;Gopi Elango ,&nbsp;Michael Veness ,&nbsp;Bradley Camden ,&nbsp;David Farlow ,&nbsp;Muzib Abdul-Razak","doi":"10.1016/j.suronc.2025.102258","DOIUrl":"10.1016/j.suronc.2025.102258","url":null,"abstract":"<div><h3>Objective</h3><div>Sentinel lymph node biopsy (SLNB) is crucial in cutaneous melanoma and oral cavity squamous cell carcinoma (OCSCC) as it directs the need for systemic therapy. There has been growing interest in Technetium-99m-labeled Tilmanocept (TL) due to its specific binding capability. This study compares the efficacy of TL to ^99mTc-antimony sulphide colloid (ASC), in these two biologically distinct cancers.</div></div><div><h3>Design</h3><div>In this prospective cross-sectional study, 40 patients were included in each radiotracer group. The primary outcomes measured SN identification rate on lymphoscintigraphy and surgical node retrieval rate. Secondary outcomes include pathological status of lymph nodes, false negative rates (FNR), and nodal recurrence.</div></div><div><h3>Result</h3><div>TL had comparable outcome to ASC with a 100 % SN detection and retrieval rate. Both radiotracers had 100 % lymph nodal tissue specificity with an FNR rate of 0 % for both radiotracers in CM and 25 % for TL in OCSCC. There were significant differences between the SN detection and retrieval rates in ASC in CM and OCSCC but not TL, reflecting its superior binding capability.</div></div><div><h3>Conclusion</h3><div>Our study is the first to demonstrate the superior molecular binding capability of TL with minimal migration to the second echelon nodes.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"62 ","pages":"Article 102258"},"PeriodicalIF":2.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skeletal muscle and visceral fat density are predictive imaging biomarkers for overall survival in patients with pancreatic adenocarcinoma: A retrospective multicenter analysis","authors":"Maike Theis ,&nbsp;Wei Hong ,&nbsp;Belinda Lee ,&nbsp;Sebastian Nowak ,&nbsp;Julian Luetkens ,&nbsp;Stephen Stuckey ,&nbsp;Peter Gibbs ,&nbsp;Benjamin Thomson ,&nbsp;Michael Michael ,&nbsp;Alois Martin Sprinkart ,&nbsp;Hyun Soo Ko","doi":"10.1016/j.suronc.2025.102251","DOIUrl":"10.1016/j.suronc.2025.102251","url":null,"abstract":"<div><h3>Rationale and objectives</h3><div>Utilizing a fully automated AI-generated body composition analysis (BCA) from PDAC staging computed tomography (CT) imaging to discover predictive imaging biomarkers for overall survival (OS).</div></div><div><h3>Material and methods</h3><div>Routine PDAC staging CTs (07/2012–12/2020) and clinicopathological data (Eastern Cooperative Oncology Group (ECOG) performance status, resection status, chemotherapy, age, CA19–9, Charlson Comorbidity Index, BMI) from four tertiary centers were collected retrospectively. Using a 3:1 split (training:holdout), we fitted Cox regression OS using every possible combination of 7 clinicopathological and 9 BCA variables: skeletal muscle index (SMI), area and density of total muscle compartment (TMC), skeletal muscle (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and selected the combination with the lowest information complexity (ICOMP). The added value of BCA was calculated by comparing the BCA model with the base model (without BCA variables).</div></div><div><h3>Results</h3><div>Analysis included 472 PDAC patients (213 female, mean age 67.9 ± 11.5 years, resectable n = 170, unresectable n = 106, metastatic n = 196). Four clinicopathological (ECOG, resection status, chemotherapy, CA19–9) and 5 BCA variables (SMI, SM density, VAT density, TMC area, VAT area) were selected. Decreased SM density (myosteatosis) and increased VAT density showed strong association with OS (p = 0.0094 and 0.0019, respectively). The BCA model showed superior performance compared to the base model in all subgroups (AUC: resectable 0.76 versus 0.70, unresectable 0.76 versus 0.69, and metastatic 0.80 versus 0.75).</div></div><div><h3>Conclusion</h3><div>BCA-identified myosteatosis and increased VAT density to be predictive imaging biomarkers for OS in all PDAC subgroups, potentially adding value to upfront risk stratification.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102251"},"PeriodicalIF":2.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144480295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative prediction of severe short-term complications in patients with bladder cancer undergoing radical cystectomy","authors":"Thomas Vetsch ,&nbsp;Markus Huber ,&nbsp;Patrick Y. Wuethrich ,&nbsp;Marc A. Furrer","doi":"10.1016/j.suronc.2025.102253","DOIUrl":"10.1016/j.suronc.2025.102253","url":null,"abstract":"<div><h3>Background and objective</h3><div>Radical cystectomy (RC) is associated with a high risk of postoperative complications. The prediction of individual patient risk for severe complications can facilitate preoperative shared decision-making. Patients with elevated risk may be referred to prehabilitation with the aim to mitigate the risk to improve perioperative outcomes. We developed models to predict severe short-term postoperative complications using preoperatively available clinical variables.</div></div><div><h3>Methods</h3><div>Data from a prospective cohort of 1313 RC patients treated between 1999 and 2021 was used. Preoperative demographic, laboratory, and cancer-related variables were defined as domains to predict severe complications measured by the Comprehensive Complication Index (CCI). Machine-learning models were trained for each postoperative day and predictor domain. The area under the receiver operating characteristic curve (AUROC) was reported as the primary outcome. Clinical utility was examined using Decision Curve Analysis (DCA).</div></div><div><h3>Results</h3><div>The best performing model had an AUROC of 0.69 (95 % CI 0.63–0.75) for severe complications on postoperative day (POD) 14. Mean AUROCs across POD 1–30 were 0.64 for all variables combined, 0.58 for demographics, 0.56 for laboratory values, and 0.53 for cancer-related factors. Model calibration and stability improved from POD 10 onwards. Decision curve analysis indicated the highest net benefit from models incorporating all predictors, with demographic variables contributing most among individual domains.</div></div><div><h3>Conclusions and clinical implications</h3><div>Limited clinical utility of the trained models was observed. The benefit for preoperative clinical decision-making is unclear. Clinical utility may improve by the inclusion of variables related to function in future models (e.g., frailty).</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102253"},"PeriodicalIF":2.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes and pathologic complete response following neoadjuvant chemoradiotherapy versus chemotherapy alone in locally advanced rectal cancer","authors":"Metincan Erkaya ,&nbsp;Cigdem Benlice ,&nbsp;Bilgi Baca ,&nbsp;Emre Gorgun","doi":"10.1016/j.suronc.2025.102252","DOIUrl":"10.1016/j.suronc.2025.102252","url":null,"abstract":"<div><h3>Background</h3><div>The management of locally advanced rectal cancer (LARC) continues to evolve, marked by significant advancements in treatment paradigms. Total neoadjuvant therapy (TNT) has emerged as a promising strategy, while de-escalation approaches, such as neoadjuvant chemotherapy (nCT) alone, are gaining traction to mitigate radiation-related toxicities without compromising oncologic efficacy. This study aimed to compare survival outcomes and pathologic complete response (pCR) rates between patients with LARC treated with neoadjuvant chemoradiotherapy (nCRT) and those treated with nCT alone.</div></div><div><h3>Methods</h3><div>This retrospective cohort study analyzed data from the National Cancer Database (NCDB) between 2015 and 2019. The inclusion criteria were non-metastatic clinical T2 node-positive, T3 node-negative, and T3 node-positive rectal adenocarcinoma patients undergoing partial proctectomy with neoadjuvant therapy. The stabilized inverse probability of treatment weighting (IPTW) was applied to balance the baseline characteristics. Overall survival was assessed using Kaplan-Meier curves and multivariable Cox proportional hazards models, while pCR rates were analyzed using logistic regression.</div></div><div><h3>Results</h3><div>Of 6886 patients included, 386 (5.6 %) received nCT alone, and 6500 (94.4 %) received nCRT. After IPTW adjustment, no significant difference in overall survival was observed between nCRT and nCT alone groups (HR: 0.99, 95 % CI: 0.69–1.41, p = 0.936). pCR rates were similar (OR: 1.20, 95 % CI: 0.77–1.98, p = 0.438). Subgroup analysis revealed non-significant trends toward higher pCR rates with nCRT in T3 node-positive patients (OR: 1.44, 95 % CI: 0.77–3.05, p = 0.297). Residual tumor margins (HR: 3.04, 95 % CI: 2.34–3.94, p &lt; 0.001) and incomplete pathological response (HR: 1.68, 95 % CI: 1.22–2.31, p = 0.002) were significant predictors of worse survival outcomes regardless of treatment modality.</div></div><div><h3>Conclusion</h3><div>This large-scale analysis demonstrates comparable overall survival and pCR rates between nCRT and nCT alone in carefully selected with LARC patients, supporting the growing evidence for selective radiation omission strategies. These findings align with those of contemporary de-escalation trials and suggest that nCT alone may be a viable treatment option for specific patient subgroups. Future prospective studies incorporating quality of life assessments and long-term functional outcomes are essential to optimize personalized treatment strategies and refine patient selection criteria for radiation de-escalation in LARC management.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102252"},"PeriodicalIF":2.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144480296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Octogenarians with lower BMI have comparatively poor survival in potentially resectable pancreatic cancer: outcomes over 5-year follow-up","authors":"Hideki Motobayashi,&nbsp;Atsushi Shimizu,&nbsp;Yuji Kitahata,&nbsp;Akihiro Takeuchi,&nbsp;Tomohiro Yoshimura,&nbsp;Masatoshi Sato,&nbsp;Kyohei Matsumoto,&nbsp;Shinya Hayami,&nbsp;Atsushi Miyamoto,&nbsp;Kensuke Nakamura,&nbsp;Manabu Kawai","doi":"10.1016/j.suronc.2025.102248","DOIUrl":"10.1016/j.suronc.2025.102248","url":null,"abstract":"<div><h3>Background</h3><div>The indication and benefit of pancreatectomy for octogenarians with pancreatic cancer remains controversial. This study aims to evaluate prognostic factors in patients with pancreatic cancer after 5-year follow-up.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the 229 patients who underwent pancreatectomy at our hospital between 2005 and 2018 for potentially resectable pancreatic cancer. Of these, 216 patients were divided into three groups based on age: &lt;70 years old (n = 97), 70–79 years old (n = 81), and ≥80 years old (n = 38).</div></div><div><h3>Results</h3><div>Seventy patients (32.4 %) achieved 5-year survival. Median survival time and five-year overall survival in each group were: 37.3 months and 37.1 % for patients &lt;70 years old, 26.0 months and 30.9 % for those 70–79 years old, and 20.2 months and 23.7 % for those ≥80 years old. The patients who were ≥80 years old and had BMI &lt;20 kg/m² had a significantly poorer prognosis than those &lt;80 years old and who had BMI ≥20 kg/m² (<em>P</em> = 0.006). Independent prognostic factors were age ≥80 years and BMI &lt;20 kg/m², preoperative CA19-9 ≥ 500 IU/L, transfusion, tumor size ≥20 mm, positive lymph node, and non-completion of adjuvant therapy. Moreover, age ≥80 years, BMI &lt;20 kg/m², preoperative CA19-9, and severe complications were each associated with non-completion of adjuvant therapy.</div></div><div><h3>Conclusions</h3><div>Octogenarians with lower BMI, which might be attributed to lower completion rate of adjuvant therapy, had especially poorer prognosis.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102248"},"PeriodicalIF":2.3,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 1 study of intra-arterial CBL0137 in extremity melanomas and sarcomas","authors":"Joseph J. Skitzki ,&nbsp;Minhyung Kim ,&nbsp;Daniel T. Fisher ,&nbsp;John M. Kane III ,&nbsp;Han Yu ,&nbsp;Kayla Catalfamo ,&nbsp;Garin Tomaszewski ,&nbsp;Michael Petroziello ,&nbsp;Andrei Purmal ,&nbsp;Katerina V. Gurova ,&nbsp;Andrei V. Gudkov","doi":"10.1016/j.suronc.2025.102243","DOIUrl":"10.1016/j.suronc.2025.102243","url":null,"abstract":"<div><h3>Introduction</h3><div>Regional therapies for cancer leverage the ability to isolate the circulation to a diseased extremity or organ and deliver high doses of chemotherapy that would be systemically prohibitive due to toxicity. Virtually all regional therapies utilize the original chemotherapy agent, melphalan, which requires circulatory isolation. CBL0137 is a small molecule with multiple anti-tumor effects when given intra-arterially (IA) that shows similar efficacy to melphalan in preclinical models, but without the need for circulatory isolation.</div></div><div><h3>Materials and methods</h3><div>Patients with advanced, unresectable melanoma or sarcoma (n = 5, sarcoma 60 %, melanoma 40 %) of the extremity entered a rapid dose-escalation phase of a clinical trial of IA CBL0137. CBL0137 was administered via a single IA catheter placed proximal to the site of tumor(s) in the affected extremity and delivered over 15 min. Primary objective was to define dose-limiting toxicities with secondary objectives of assessing response and pharmacokinetics (PK).</div></div><div><h3>Results</h3><div>The treatments were well tolerated with minimal to no toxicity for all patients. PK data showed predictable, dose-dependent drug exposures with rapid tissue uptake and markedly decreased systemic concentrations as compared to matched intravenous dosing data. CBL0137 preferentially accumulated within tumor tissue as compared to surrounding normal tissue in the infused limb without the need for tourniquet. Sixty percent of patients treated in this protocol would not have been eligible for standard regional therapies with one patient demonstrating prolonged disease stability while avoiding major amputation.</div></div><div><h3>Conclusions</h3><div>The historic restrictions of standard regional therapies may be overcome with IA CBL0137, and this treatment is potentially applicable to a wide range of cancers beyond the extremities.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102243"},"PeriodicalIF":2.3,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal aortic calcification predicts poor prognosis for patients with gastric cancer who underwent curative gastrectomy","authors":"Naoko Fukushima ,&nbsp;Takahiro Masuda ,&nbsp;Kenei Furukawa ,&nbsp;Kazuto Tsuboi ,&nbsp;Masami Yuda ,&nbsp;Keita Takahashi ,&nbsp;Masaichi Ogawa ,&nbsp;Toru Ikegami ,&nbsp;Fumiaki Yano ,&nbsp;Ken Eto","doi":"10.1016/j.suronc.2025.102247","DOIUrl":"10.1016/j.suronc.2025.102247","url":null,"abstract":"<div><h3>Background</h3><div>Abdominal aortic calcification is a pathological vascular disorder associated with various diseases and has recently been associated with the prognosis of various cancers. This study aimed to investigate the association between abdominal aortic calcification and prognosis in patients who underwent curative gastrectomy for gastric cancer.</div></div><div><h3>Methods</h3><div>We analyzed 251 patients who underwent curative gastrectomy for gastric cancer between January 2014 and February 2020. The volume of abdominal aortic calcification was assessed using routine preoperative computed tomography. The cutoff values were assessed using receiver operating characteristic curve analysis of the survival status at the 3-year follow-up, and set to 585.</div></div><div><h3>Results</h3><div>Higher abdominal aortic calcification volume was identified in 151 patients (60 %). Multivariate analysis showed that abdominal aortic calcification (<em>P</em> = 0.0120, <em>P</em> = 0.0430, respectively), and stage II or III disease (<em>P</em> = 0.0000, <em>P=</em>0.0000, respectively) were independent and significant predictors of the disease-free and cancer-specific survival. Additionally, patients with higher abdominal aortic calcification volume were significantly older and had a higher prevalence of hypertension, diabetes, chronic renal failure, and cardiovascular diseases.</div></div><div><h3>Conclusions</h3><div>Abdominal aortic calcification showed a strong preoperative prognostic indicator in patients undergoing curative gastrectomy for gastric cancer.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102247"},"PeriodicalIF":2.3,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}